The comparative susceptibility of 622 recent clinical isolates of anaerobic bacteria to minocycline, doxycycline, and tetracycline was determined by an agar-dilution technique. In addition to Bacteroides fragilis, a variety of other anaerobic bacteria was resistant to achievable blood concentrations of tetracycline (55% inhibited by 6.25 gg/ml) and doxycycline (58% inhibited by 2.5 gg/ml). In contrast, minocycline was significantly more active (P < 0.05) than both doxycycline and tetracycline, and 70% of strains were inhibited by achievable blood concentrations of this antibiotic (2.5 lAg/ml). The enhanced activity of minocycline was particularly striking for Peptococcus asaccharolyticus, P. magnus, P. prevotii, Peptostreptococcus anaerobius, and Bacteroides melaninogenicus. Further evaluation of the clinical efficacy of minocycline against anaerobic infections is indicated.
With the recent development of tetracycline resistance by Bacteroides fragilis and other anaerobic bacteria (6, 9, 10, 13, 14) , this antibiotic can no longer be recommended for anaerobic infections unless the specific infecting organisms have been determined to be susceptible in vitro. Susceptibility of anaerobic bacteria to minocycline and doxycycline, however, has not been adequately studied. These two analogues of tetracycline possess pharmacological attributes, such as enhanced absorption and tissue penetration, which may conceivably improve their in vivo effectiveness (2, 5) . Furthermore, both minocycline and doxycycline have been demonstrated to be considerably more active than the parent compound against a variety of aerobic bacteria (7, 12) . The present study was undertaken, therefore, to determine the comparative susceptibility of 622 recent clinical isolates of anaerobic bacteria to minocycline, doxycycline, and tetracycline.
MATERIALS AND METHODS
All anaerobic bacteria tested were clinical isolates recovered from inpatients of Harbor General Hospital during (Table 1) (1) , previously determined to approximate 10 to 107 organisms/ml by colony counting in roll tubes and prereduced anaerobically sterilized media. Inocula (0.0025 ml) were delivered with a Steers replicating apparatus (11) . Plates were incubated at 37 C in anaerobic jars after air had been evacuated and replaced with a gas mixture containing 80% nitrogen, 10% hydrogen, and 10% carbon dioxide. Anaerobic, microaerophilic (incubated in candle jars), and aerobic plates without antibiotics were used for controls, and a reference strain with known minimal inhibitory concentration was included in each run for reproducibility. All results were read at 48 h, and the minimal inhibitory concentration recorded was the least antibiotic concentration which yielded no visible growth. I RESULTS both doxycycline and tetracycline was found with relative frequency among all genera and Cumulative percent of 622 strains of anaero-species of anaerobic bacteria other than bic bacteria inhibited at various concentrations Propionibacterium. In contrast, minocycline of minocycline, doxycycline, and tetracycline is was significantly more effective (P < 0.05 by x' presented in Table 2 . The median minimal analysis) than both doxycycline and tetracyinhibitory concentration of all isolates was 0.3 cline, and 70% of strains were inhibited by 2.5 jsg/ml for minocycline, 1.3 gg/ml for doxycy-gg/ml, a concentration readily achievable in cline, and 3.8 ,ug/ml for tetracycline. Compara-blood after therapeutic doses of minocycline (4). ble percentages of organisms were inhibited by Specifically, minocycline was significantly more achievable blood concentrations of doxycycline active (P < 0.05 by x2 analysis) than both (58% inhibited by 2.5 sg/ml) and tetracycline doxycycline and tetracycline for Peptococcus (55% inhibited by 6.25,g/ml), and resistance to asaccharolyticus, P. magnus, and P. prevotii Peptostreptococcus  93  42  61  78  97 21  48  69 91 28  44  67  86  anaerobius  51  39  65  88°100 23  47  74 96 23  35  69  94  micros  27  55  59  67  96 26  56  67 89 52  67  67  81  intermedius  11  27  54  64  91  9  36  45 82  0  36  54  64  other  4  25  50  75  75  0  50  75 75  0  25  75  75  Ruminococcus  7  43  57  57 100 28  43  57 86 28  57  57  71  Acidaminococcus  12  33  58  75 100 25  50  58 83  17  50  58  92  Veillonella  8  37  62  75  75 25  50  62 87 25  62  62  75  Clostridium  29  41  55  65  90 27  48  62 86 17  31  48  76  perfringens  13  54  54  61  85 23  54  54 77 15  38  54  92  other  16  31  56  69  94 31  44  69 94  19 26 44  62  Propionibacterium  75  77  87  91  99 31  72  83 97 24  75  81  93  acnes  61  79  87  90  98 31  70  80 97 28  75  82  92  granulosum  10  80  90 100 100 40  80 100 100 10  80  80 100  other  4 '50  75  75 100  0  75  75 100  0  50  75 100  Eubacterium  46  41  59  76  96 33  41  54 93 28  48  67  80  lentum  29  41  59  76 100 41  52  59 96 31  55  65  79  other  17  41  59  76  88 18  23  47 88 23  35  70  82  Lactobacillus  21  24  71  81 100 24  38  71 95 19  48  67  90  Bifidobacterium  11  36  54  54  91  9  45  54 64  0  54  54  73  Actinomyces  6  33  67  67  83 33  33  33 67 (9, 10, 14, 15) . These data illustrate the importance of susceptibility testing of current clinical isolates as a guide to rational antimicrobial therapy and further caution against the indiscriminant use of tetracycline for anaerobic infections. These data also suggest that, although doxycycline is three times more active than tetracycline, this apparent advantage is offset by lower concentrations achievable in blood by therapeutic doses of doxycycline (2.5 ug of doxycycline per ml versus 6.25 ,ug of tetracycline per ml) (8) . Hence, doxycyline is not likely to offer significant advantage over tetracycline unless at least twice the serum concentrations attainable with currently recommended doses of doxycycline can be safely achieved. Minocycline; on the other hand, is distinctly more active than both tetracycline and doxycycline and appears to be particularly effective against B. melaninogenicus, Fusobacterium, certain species of Peptococcus and Peptostreptococcus, and nonsporeforming gram-positive bacilli. In view of this and the excellent penetration of minocycline into brain and other tissues (5) , further evaluation of the clinical efficacy of this antibiotic against anaerobic infections is clearly indicated.
